Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term dapagliflozin treatment and endothelial function in non-diabetic heart failure
MOH_2021-01-03_009588Phase 4Not yet recruiting
- Sponsor
- ד"ר אבישי גרופר
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapagliflozin in heart failure (HF), sponsored by ד"ר אבישי גרופר. Primary endpoint: Change in endothelial function after 3 months of dapagliflozin. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on MOH_2021-01-03_009588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-03_009588.